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Current strategies for preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 50 
infections are limited to non-pharmacological interventions. Hydroxychloroquine (HCQ) has been 51 
proposed as a postexposure therapy to prevent Coronavirus disease 2019 (Covid-19) but definitive 52 
evidence is lacking. 53 
Methods 54 
We conducted an open-label, cluster-randomized trial including asymptomatic contacts exposed to a 55 
PCR-positive Covid-19 case in Catalonia, Spain. Clusters were randomized to receive no specific therapy 56 
(control arm) or HCQ 800mg once, followed by 400mg daily for 6 days (intervention arm). The primary 57 
outcome was PCR-confirmed symptomatic Covid-19 within 14 days. The secondary outcome was SARS-58 
CoV-2 infection, either symptomatically compatible or a PCR-positive result regardless of symptoms. 59 
Adverse events (AEs) were assessed up to 28 days. 60 
Results 61 
The analysis included 2,314 healthy contacts of 672 Covid-19 index cases identified between Mar 17 and 62 
Apr 28, 2020. A total of 1,198 were randomly allocated to usual care and 1,116 to HCQ therapy. There 63 
was no significant difference in the primary outcome of PCR-confirmed, symptomatic Covid-19 disease 64 
(6.2% usual care vs. 5.7% HCQ; risk ratio 0.89 [95% confidence interval 0.54-1.46]), nor evidence of 65 
beneficial effects on prevention of SARS-CoV-2 transmission (17.8% usual care vs. 18.7% HCQ). The 66 
incidence of AEs was higher in the intervention arm than in the control arm (5.9% usual care vs 51.6% 67 
HCQ), but no treatment-related serious AEs were reported. 68 
Conclusions 69 
Postexposure therapy with HCQ did not prevent SARS-CoV-2 disease and infection in healthy 70 
individuals exposed to a PCR-positive case. Our findings do not support HCQ as postexposure 71 
prophylaxis for Covid-19. 72 
 73 
ClinicalTrials.gov registration number: NCT04304053 74 
 75 
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Coronavirus 2019 disease (Covid-19) is a rapidly emerging infection caused by the severe acute 77 
respiratory syndrome coronavirus 2 (SARS-CoV-2). The rate of new cases among contacts (secondary 78 
attack rate) has been estimated as 10 to 15%.1-4 The current infection control strategy is based on social 79 
distancing and isolation of cases and contacts.5 The effectiveness of the latter depends on the promptness 80 
of the intervention, level of contact tracing, and level of isolation compliance.6 Unfortunately, real-world 81 
constraints for implementing full effective measures have resulted in SARS-CoV-2 spread in many 82 
countries.  83 
Postexposure prophylaxis of healthy contacts is among the measures used for outbreak control of several 84 
infectious diseases, for example, in pandemic influenza.7 No agent is known to be effective in preventing 85 
SARS-CoV-2 infection or disease, but several drugs have shown antiviral activity in the laboratory, 86 
including the aminoquinolines hydroxychloroquine (HCQ) and chloroquine.8 In-vitro results showed that 87 
these drugs block the SARS-CoV-2 viral spread in cell cultures9–11 and that HCQ was more effective at 88 
impairing SARS-CoV-2 viral replication compared to chloroquine.11 To date, only one RCT has reported 89 
on HCQ for postexposure prophylaxis for Covid-19.12 However, concerns have been raised about the trial 90 
design, primarily because most participants were diagnosed with an influenza-like illness based on 91 
symptoms alone, and only 20% of their Covid-19 outcome was confirmed with PCR. 92 
We investigated the efficacy and safety of HCQ to prevent secondary PCR-confirmed symptomatic 93 
Covid-19 (confirmed Covid-19) and SARS-CoV-2 infection in contacts exposed to a PCR-positive 94 
Covid-19 case during the outbreak in Catalonia, the region with the second highest number of Covid-19 95 
cases in Spain.  96 
 97 
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We included adult individuals ≥ 18 years of age with a recent history of close contact exposure to a PCR-100 
confirmed Covid-19 case (i.e., > 15 minutes within two meters, up to seven days before enrolment) and 101 
absence of Covid-19-like symptoms on the two weeks preceding enrolment, as either a healthcare worker, 102 
a household contact, a nursing home worker or a nursing home resident. Contacts with Covid-19-like 103 
signs and symptoms at the time of the baseline visit were considered unpreventable Covid-19 events and 104 
were not enrolled in the study. All eligibility criteria are listed in the Supplementary Appendix. 105 
TRIAL DESIGN AND OVERSIGHT 106 
This was an open-label, phase 3 cluster-randomized trial conducted from Mar 17 to Apr 28, 2020, during 107 
the Covid-19 outbreak, in three out of nine health administrative regions in Catalonia, Spain: Catalunya 108 
central, Àmbit Metropolità Nord, and Barcelona Ciutat (total target population 4,206,440 people; Fig. S1, 109 
Supplementary Appendix). 110 
Study candidates were screened using the electronic registry of the Epidemiological Surveillance 111 
Emergency Service of Catalonia (SUVEC) of the Department of Health. During the Covid-19 outbreak in 112 
Catalonia, a public health ordinance required all patients who tested positive for Covid-19 in any of the 113 
designated diagnostic laboratories to be notified to the SUVEC.13   114 
The study protocol and subsequent amendments, available at NEJM.org, were approved by the 115 
institutional review board of Hospital Germans Trias Pujol, and the Spanish Agency of Medicines and 116 
Medical Devices. All participants provided written informed consent. 117 
TRIAL PROCEDURES 118 
Following a similar approach as the ring vaccination trial “Ebola Ça Suffit!”,14 we defined study clusters 119 
(called rings) of healthy individuals (contacts) epidemiologically linked to a PCR-positive Covid-19 case 120 
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(index case). All contacts in a ring were simultaneously cluster-randomized (1:1) to either a control arm 121 
or an intervention arm. Randomization was performed remotely by a member of the study team not 122 
involved in participants’ enrollment. Following ring randomization, we verified the selection criteria of 123 
individual candidates and obtained informed consent for enrollment. The allocation was revealed to 124 
participants after providing written consent on day 1 (baseline). Participants allocated in the control arm 125 
received no treatment aside from usual care, whereas those in the intervention arm received HCQ 126 
(Dolquine®) 800 mg on day 1, followed by 400 mg once daily for six days. The dose and regimen of HCQ 127 
were chosen based on pharmacokinetic simulations to achieve plasma and lung concentrations above the 128 
SARS-CoV-2 half-maximal effective concentration observed in-vitro11 for 14 days (details provided in 129 
the Study Protocol). 130 
By the time of trial conduct, quarantine was mandatory for all exposed contacts, according to the National 131 
Department of Health guidelines; hence the likelihood that a participant could be exposed to other cases 132 
was low. Covid-19 index cases that generated the rings were enrolled in a nested trial aimed at 133 
investigating the efficacy of early treatment with hydroxychloroquine as therapeutic intervention for 134 
Covid-19 outpatients. Laboratory technicians were unaware of participants’ treatment, treatment 135 
response, and previous PCR results during the entire follow-up period.  136 
All contacts were visited at home or workplace on day 1 for medical exam, and baseline nasopharyngeal 137 
swab collection for SARS-CoV-2 RT-PCR test and viral load. Symptoms surveillance consisted of active 138 
monitoring by phone on days 3 and 7, and passive monitoring whenever the participant developed 139 
symptoms (i.e., participants were advised to call the research team). Participants who developed 140 
symptoms were visited the same day (unscheduled visit) by the outbreak field team for nasopharyngeal 141 
swab collection. All participants were visited at home on day 14 for nasopharyngeal swab collection, and 142 
finger-prick for IgM/IgG rapid test. Safety, medication adherence  (i.e., treatment and number of doses 143 
taken), and crossover (i.e., unplanned conversion of control to intervention) were assessed using self-144 
reports collected in telephone interviews on days 3, 7, and 28. Details on procedures performed at each 145 
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visit and laboratory methods for SARS-CoV-2 identification and quantification (Fig. S2) are provided in 146 
the Supplementary Appendix. 147 
OUTCOMES 148 
The primary outcome was the onset of a confirmed Covid-19 episode, defined as symptomatic illness (at 149 
least one of the following symptoms: fever, cough, difficulty breathing, myalgia, headache, sore throat, 150 
new olfactory and taste disorder(s), or diarrhea) and a positive SARS-CoV-2 RT-PCR test. The primary 151 
outcome was assessed in all asymptomatic individuals, irrespective of the PCR result; in a post hoc 152 
analysis, we explored the outcome in individuals with positive and negative PCR separately. Time-to-153 
event was defined as the number of days from the date of randomization/exposure to the confirmed date 154 
of the onset of symptomatic illness.  155 
The secondary outcome was the incidence of SARS-CoV-2 infection, defined as either the RT-PCR 156 
detection of SARS-CoV-2 in a nasopharyngeal specimen or the presence of any of the aforementioned 157 
symptoms compatible with Covid-19. The rationale for this outcome was to encompass definitions of 158 
Covid-19 used elsewhere12,15 and all possible viral dynamics. We, therefore, assumed that if clinical 159 
suspicion is high, infection should not be ruled out based on a negative PCR alone―particularly early in 160 
the course of infection.15 Participants who were hospitalized or died and whose hospital/vital records 161 
listed Covid-19 as the main diagnosis (including PCR confirmation) were also considered for the primary 162 
and secondary outcomes. We also measured serological positivity (IgM/IgG) of contacts at day 14. Safety 163 
outcomes included the frequency and severity of adverse events (AE), serious AE (SAE), and AE of 164 
special interest (e.g., cardiac) up to 28 days from treatment start. Causality was assessed by an external 165 
panel of pharmacovigilance consultants. 166 
STATISTICAL ANALYSIS 167 
With an enrollment target of 95 clusters per trial group16 ―15 participants per cluster and intraclass 168 
correlation of 1.0― the initial design yielded 90% power to detect a difference of 10% in the incidence, 169 
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with expected incidence of 15% in the control arm. Owing to the limited information available by March 170 
2020 regarding the cluster size and the incidence of Covid-19 after exposure, the protocol prespecified a 171 
sample-size re-estimation at the interim analysis. This re-estimation was aimed at maintaining the ability 172 
(80% power) to detect a reduction from 6.5% to 3% of the primary outcome, yielding 320 clusters per 173 
trial group with 3.5 participants per cluster.  174 
The primary efficacy analysis was performed on the intention-to-treat (ITT) population, which included 175 
all randomized subjects with complete outcome data. We decided not to impute outcome data to 176 
participants with missing measurements because this approach would have biased the incidence of 177 
secondary Covid-19 events. Sensitivity analyses were performed with the per-protocol (PP) population in 178 
participants who completed the trial according to the protocol. The safety population included all 179 
participants who received any trial intervention, including usual care. 180 
The cumulative incidence in primary, secondary, and safety outcomes was compared at the individual 181 
level using a binomial regression model with robust sandwich standard errors to account for clustering 182 
within rings.17 We defined a generalized linear model with a binomial distribution and a logarithm link 183 
function to estimate the relative risk (RR) as a measure of effect.18 The individual-level variables we 184 
adjusted for are age, gender, region, and time of exposure. We did additional pre-specified analyses to 185 
assess the consistency of treatment effects in subgroups defined according to the viral load of the contact 186 
at baseline, viral load of the index case, place of exposure, time of exposure to the index case. Survival 187 
curves by study groups on time-to-event outcomes were compared using a Cox proportional hazards 188 
model with a cluster-level frailty term to adjust for clustering.19 The significance threshold was set at a 189 
two-sided alpha value of 0.05, unless otherwise indicated, and all statistical analyses were conducted in R 190 
version 3.6.2.20 191 
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CHARACTERISTICS OF STUDY PARTICIPANTS 193 
Between Mar 17 and Apr 28, 2020, we assessed 754 Covid-19 index cases for eligibility; 672 of them 194 
were selected for defining the corresponding clusters, which included 4,399 contacts (Fig. 1). 1,874 195 
(42.6%) of the 4,399 contacts were not enrolled because of at least one exclusion criteria, including 196 
contacts presenting Covid-19-like symptoms before enrolment (n = 537).  Additionally, 211 (8.4%) of 197 
2,525 enrolled contacts were excluded from ITT analysis because of screening failure or missing PCR 198 
results on day 14, yielding an ITT population of 2,314 contacts. During follow-up, 64 participants had a 199 
protocol deviation regarding the intervention (PP population of 2,250 contacts). 200 
The demographic, clinical, and epidemiological characteristics of participants at baseline were similar in 201 
the two study arms (Table 1, PP analysis in the Supplementary Appendix). The mean age of contacts was 202 
48.6 years (SD 19.0) and the PCR test at baseline was negative in 87.8% of them (2,000 of 2,314). 203 
Overall, 55.6% of the participants (1,287 of 2,314) reported chronic health conditions. The median length 204 
from exposure to enrolment was 4.0 (IQR 3.0–6.0) days. The size of clusters was similar in both arms 205 
(median 2.0 vs. 2.0; P = 0.25). Exposure was predominantly from an index case with moderate-to-high 206 
viral load shedding (460 of 549 [83.8%] index cases with available viral load assessment). Health care 207 
workers and nursing home workers accounted for 60.3% (1,395) of the participants; 27.7% (640) were 208 
enrolled as household contacts, and 12.7% (293) as nursing home residents. Overall, 67.2% (1,555) of 209 
participants reported routine use of masks at the time of exposure, and 6.2% (144) of contacts continued 210 
to sleep in the same room as the index case. 211 
PRIMARY OUTCOME 212 
During the 14-day follow-up, 138 (6.0%) of 2,314 participants experienced a PCR-confirmed, 213 
symptomatic Covid-19 episode. The primary outcome was similar in the control arm (6.2%; 74/1,198) 214 
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and the intervention arm (5.7%; 64/1,116; RR 0.89 [95% CI 0.54–1.46]) (Table 2). The incidence of each 215 
of the components of the primary outcome did not differ significantly between groups. 216 
Overall, the incidence of confirmed Covid-19 was higher in participants who tested positive in the 217 
baseline PCR (Table 2); 3.4% (74 of 2,000) participants with a negative PCR at baseline and 21.9% (61 218 
of 279) participants with a positive PCR at baseline met the primary outcome criteria. The intervention 219 
was ineffective, regardless of the PCR result at baseline. 220 
We observed an overall increased risk of Covid-19 with increasing viral load of the participant at baseline 221 
(Fig. 2A) and increasing viral load of the index case (Fig. 2B). The viral load of contacts who developed 222 
confirmed Covid-19 increased 4 log10 copies/mL throughout the follow-up, whereas that of contacts 223 
without Covid-19 remained unchanged (Fig. 2C). Pre-specified subgroup analysis of the primary outcome 224 
did not reveal between-group differences in the risk of Covid-19 according to the viral load of the 225 
participant at baseline, the viral load of the index case, the length of exposure, or the place of contact (Fig. 226 
3).  227 
The survival analysis of the time to the primary outcome showed similar patterns in the two arms 228 
regarding confirmed Covid-19 onset from enrolment (median 14.0 vs. 14,0 days in the control and 229 
intervention arms, respectively; HR 0.9 [95%CI 0.6–1.5]) and from exposure (median 18.0 vs. 18.0 days; 230 
HR 1.0 [0.6–1.6]) (Fig. S3).  231 
SECONDARY OUTCOMES 232 
Of the 2,000 participants who tested negative for SARS-CoV-2 in the baseline PCR, 364 (18.2%) either 233 
became PCR positive or developed symptoms compatible with Covid-19 throughout the follow-up period 234 
(secondary outcome, Table 2), without differences between study arms (17.8%, 185/1,042 control vs. 235 
18.7%, 179/958 intervention; RR 1.04 [95%CI 0.77 1.41]). The virus-specific IgG/IgM positivity was 236 
higher in the intervention arm than in the control arm (6.7%, 70/1,042 control vs. 10.4% 100/958). Of 125 237 
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participants who became PCR-positive during follow-up, 30 (24.0%) were seropositive on day 14 (Fig 238 
S4). 239 
ADHERENCE AND SAFETY 240 
Full adherence for the trial intervention was 97.5% (1,268 of 1,300) in the control arm and 95.1% (1,138 241 
of 1,1197) in the intervention arm. In the safety population, 77/1,300 (5.9%) participants in the control 242 
arm and 671/1,197 (51.6%) in the intervention arm experienced at least one AE during 14 days of follow-243 
up (Table 3). The most frequent treatment-related AEs among participants given HCQ were 244 
gastrointestinal (diarrhea, nausea, and abdominal pain) and nervous system disorders (drowsiness, 245 
headache, and metallic taste) (Tables S4). Thirty-one SAE were reported, 17 in the control arm and 14 in 246 
the intervention arm, none of them related to HCQ (Table S5). Six AEs of special interest were observed, 247 
including five episodes of self-limited palpitations potentially related to treatment (Table S6). Relevant 248 
safety data listings are provided in the Supplementary Appendix. 249 
 250 
DISCUSSION 251 
Postexposure prophylaxis with HCQ did not prevent Covid-19 disease or SARS-CoV-2 infection in 252 
asymptomatic contacts exposed to a PCR-positive index case. In our cohort, the overall attack rate for the 253 
PCR-confirmed symptomatic Covid-19 was 6.0%, excluding subjects that were not enrolled because had 254 
symptoms before the baseline assessment. HCQ did not decrease the incidence of confirmed Covid-19 255 
disease among contacts (6.2 vs. 5.7%). Our trial tested two possible effects of postexposure therapy: 256 
prophylaxis in contacts with negative PCR at baseline, and preemptive therapy in contacts with positive 257 
PCR at baseline (i.e., prevent progression of asymptomatic infection to disease). This dual scenario 258 
mirrors a real-life setting, where the PCR result of people exposed to a known Covid-19 case is usually 259 
not available immediately. Among PCR positive contacts at baseline (12% of subjects), the intervention 260 
had no apparent efficacy as early preemptive therapy. Of note a baseline positive PCR result significantly 261 
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increased the risk of developing Covid-19 in our cohort, but a high proportion of participants with this lab 262 
result (79%) did not go on to develop symptomatic disease, thus reinforcing the need to quarantine or to 263 
increase testing of contacts even if asymptomatic. Also, of importance to the public health decision-264 
making is that high Covid-19 viral load (>108 log10 copies/mL (SD) results in more risk of transmission to 265 
contacts. 266 
The intervention also did not reduce the transmission of SARS-CoV-2 (17.8% vs. 18.7%) or incidence of 267 
seropositivity. Notably, the overlap of positive PCR and positive serology was low, which could be 268 
related to both, the reported low rate of seroconversion in asymptomatic contacts21 or the higher risk of 269 
false negative PCR result on the initial stage of infection.15 Regarding safety, we observed a higher 270 
incidence of AE in the treatment group, albeit with low severity. This is an open-label study where the 271 
psychological components in the treated group cannot be excluded. Furthermore, the side effects reported 272 
were mainly at gastrointestinal level, while only five (0.3%) out of 1,479 events could be considered 273 
cardiac, thus not confirming previously published data that raised safety concerns.22 The safety results 274 
need to be interpreted considering the dose used, length of treatment, and the lack of ECG monitoring in 275 
the study. 276 
The strengths of this study are the use of PCR and viral load titration at baseline, at day 14, and 277 
potentially when ill, and the measurement of viral load of the source index case to estimate risk of 278 
transmission. In addition, we included elderly persons (e.g. ages >90 years of age) from nursing homes.  279 
The study has some limitations. Unlike the common procedure in clinical trials, the informed consent 280 
signature took place after cluster-randomization. Nevertheless, allocation was revealed to participants 281 
after consent signature, therefore we believe the allocation concealment strategy was appropriate to 282 
prevent study participants from choosing to participate or not to participate. Owing to the urgency, the 283 
trial could not be masked with a placebo, which affected the rate of AE declared (AEs  are not commonly 284 
reported in the control, non-placebo group), but it did not affect the attrition numbers in the control arm. 285 
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However, it is worth mentioning that the laboratory staff who performed PCR tests remained unaware of 286 
the allocation of each sample.  287 
Despite the promising in-vitro results that placed HCQ among the leading candidates for Covid-19 288 
treatment and prophylaxis, 23–25 to date there is no strong argument to suggest that HCQ is effective. We 289 
provide high-quality evidence on the lack of efficacy of postexposure prophylaxis therapy with HCQ to 290 
prevent Covid-19 disease or SARS-CoV-2 infection. The data presented in this report is particularly 291 
valuable for the scientific community and policymakers involved in controlling the pandemic at the 292 
population level. Our findings encourage directing efforts to other antiviral candidates for postexposure 293 
prophylaxis. 294 
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Figure legends 395 
 396 
 397 
Figure 1. Flow diagram of individual selection and allocation. 398 
 399 
Legend. The safety population (n=2,497; 1,300 in the control arm and 1,197 in the intervention arm) 400 
included all individuals in the ITT population (except 28 not receiving any dose of study medication) plus  401 
211 participants that received medication but were excluded from ITT because of screening-failure, or 402 
missing PCR results on Day 14. 403 
 404 
Figure 2. Association of baseline viral load of participants and viral load of their index case with 405 
breakthrough Covid-19 (ITT population)    406 
Legend. Panels A and B show the association of the participant’s viral load at baseline  (A) and viral load 407 
of the index case (B) with the likelihood of developing PCR-confirmed symptomatic Covid-19 in the 408 
overall intention-to-treat population (aggregated data for the control and intervention arms). The dots are 409 
participants with (=1) or without (=0) the primary outcome of PCR-confirmed Covid-19. Panel C shows 410 
the viral load increase from baseline in participants who developed or did not develop Covid-19 (details 411 
are provided in Table S2, Supplementary Appendix). 412 
 413 
Figure 3. Subgroup analyses for the primary outcome according to risk of exposure factors (ITT 414 
population) 415 
  416 
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Table 1. Baseline characteristics of study participants (contacts) included in the intention-to-treat 418 









Individuals’ characteristics   
Age (years), mean (SD) 48.7 (19.3) 48.6 (18.7) 
Gender (female), n (%) 875 (73.0%) 813 (72.8%) 
PCR result at baseline, n (%) (N=2279) *  
 
Undetectable (< 104 copies/mL) 1042 (88.5%) 958 (86.9%) 
104-106 copies/mL 88 (7.5%) 78 (7.1%) 
107-109 copies/mL 42 (3.6%) 58 (5.3%) 
1010-1012 copies/mL 5 (0.4%) 8 (0.7%) 
Coexisting disease   
None 547 (45.7%) 480 (43.0%) 
Cardiovascular disease 178 (14.9%) 130 (11.6%) 
Respiratory disease 47 (3.9%) 64 (5.7%) 
Metabolic disease 94 (7.8%) 99 (8.9%) 
Nervous system disease 170 (14.2%) 170 (15.2%) 
Characteristics of clusters   
Number of days of exposure before enrollment, median (IQR) 4.0 (3.0, 6.0) 4.0 (3.0, 6.0) 
Number of days of exposure before the intervention, N (%)   
≤3 days 411 (34.3%) 440 (39.4%) 
4-6 days 668 (55.8%) 551 (49.3%) 
≥7 days 119 (9.9%) 125 (11.2%) 
Size of clusters, median (IQR) 2.0 (1.0, 3.0) 2.0 (1.0, 3.0) 
Viral load of the index case, n (%) (N=549)   
Undetectable (< 104 copies/mL) † 47 (16.2%) 42 (16.2%) 
104-106 copies/mL 85 (29.3%) 68 (26.3%) 
107-109 copies/mL 125 (43.1%) 129 (49.8%) 
1010-1012 copies/mL 33 (11.4%) 20 (7.7%) 
Type of contact with index case, n (%)   
Household contact 338 (28.2%) 302 (27.1%) 
Healthcare worker 130 (10.9%) 131 (11.7%) 
Nursing home worker 584 (48.7%) 550 (49.3%) 
Nursing home resident 160 (13.4%) 133 (11.9%) 
Routine use of mask, n (%)‡  
 
Yes 825 (68.9%) 730 (65.4%) 
No 256 (21.4%) 251 (22.5%) 
NA 117 (9.7%) 135 (12.1%) 
Sleeping in the same room as the index case, n (%)   
Yes 66 (5.51%) 78 (6.99%) 
No 951 (79.4%) 834 (74.7%) 
NA 181 (15.1%) 204 (18.3%) 
 421 
IQR: interquartile range (i.e., 25th and 75th percentiles). NA: not available. SD: standard deviation. 422 
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* Baseline PCR result was not available for 21 participants in the control arm and 14 participants in the intervention 423 
arm. 424 
† Pre-screening PCR was positive at the designated hospital lab prior to enrollment, but the result was negative 425 
(undetectable < 104 copies/mL) at the research lab from the swab collected on day 1. 426 
‡ Routine use of mask refers to use at the time of exposure. 427 
 428 
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  Events (%) Events (%) RR* (95% CI) 
    
Primary outcome  N=1198 N=1116  
Overall (N = 2,314)    
PCR confirmed symptomatic Covid19 74 (6.2%) 64 (5.7%) 0.89 (0.54, 1.46) 
Clinical and laboratory criteria 60 (5.0%) 49 (4.4%)  
Hospital or vital records criteria  14 (1.2%) 15 (1.3%)  
    
PCR (-) at baseline (N =2000) N=1042 N=958  
PCR-confirmed symptomatic Covid19 45 (4.3%) 29 (3.0%) 1.45 (0.73, 2.88) 
Clinical and laboratory criteria 37 (3.6%) 24 (2.5%)  
Hospital or vital records criteria  8 (0.8%) 5 (0.5%)  
    
PCR (+) at baseline (N=314) N=156 N=158  
PCR-confirmed symptomatic Covid19 29 (18.6%) 35 (22.2%) 0.96 (0.58, 1.58) 
Clinical and laboratory criteria 23 (14.7%) 25 (15.8%)  
Hospital or vital records criteria  6 (3.9%) 10 (6.3%)  
    
    
Secondary outcomes (N= 2,000) † N=1042 N=958  
Covid19 either symptomatically 
compatible or PCR positivity 
regardless of symptoms  
185 (17.8%) 179 (18.7%) 1.04 (0.77, 1.41) 
Laboratory criteria ‡ 67 (6.4%) 58 (6.1%)  
Clinical criteria   150 (14.4%) 144 (15.0%)  
Hospital or vital records criteria 8 (9.7%) 5 (0.5%)   
    
Serology positivity on day 14 91 (8.7%) 137 (14.3%) 1.6 (0.96, 2.69) 
IgM positivity 70 (6.7%) 100 (10.4%)  
IgG positivity 82 (7.9%) 118 (12.3%)  
 432 
RR: Risk ratio. CI: confidence interval. 433 
* Risk ratios are adjusted for contact-level variables (age, gender, region, and time of exposure).  434 
† Excluding PCR positive at baseline. 435 
‡ PCR confirmed either symptomatic or asymptomatic.  436 
  Symptoms compatible with Covid-19 regardless of PCR result 437 
The components of the primary and secondary outcomes are not mutually exclusive. 438 
 439 
 440 
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Table 3. No. of subjects experiencing at least one AE (Safety population). 442 
Control arm Intervention arm P-value 
 N=1,300 N=1,197  
    
Reported full adherence to trial intervention 1,268 (97.5%) 1,138 (95.1%)  
Adverse events    
Any AE 77 (5.9%) 671 (51.6%) <0.001 
Cardiac disorder (palpitations) 1 (0.1%) 5 (0.4%)  
Gastrointestinal disorder (diarrhea, abdominal 
pain, and vomiting) 33 (2.5%) 510 (42.6%) 
 
Nervous system disorder (headache, taste 
change, dizziness) 32 (2.5%) 260 (21.7%) 
 
General disorder (myalgia, fatigue, malaise) 10 (0.8%) 103 (8.6%)  
Intensity   <0.001* 
Grade 1 44 (3.4%) 573 (44.1%)  
Grade 2 14 (1.1%) 68 (5.2%)  
Grade 3 2 (0.2%) 13 (1.0%)  
Grade 4 10 (0.8%) 11 (0.8%)  
Grade 5 7 (0.5%) 6 (0.5%)  
Serious AE † 17 14  
Hospitalization 12 11  
Deaths 8 5  
Treatment-related Serious AE 0 0  
AE of special interest (cardiac) ‡ 1 5  
 443 
* overall p-value for grading  444 
† None of the serious adverse events (SAE) were adjudicated as related to HCQ by the pharmacovigilance 445 
consultants. 446 
Death and hospitalization were not mutually exclusive; five deaths occurred at the hospital while other participants 447 
died at a nursing home. 448 
‡ Cardiac disorders were all palpitations episodes; 3 of 5 events in the intervention arm were adjudicated as possibly 449 
related to the study drug by the independent pharmacovigilance consultants. Details are provided in Table S6 450 
(Supplementary material). 451 
 452 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted July 26, 2020. .https://doi.org/10.1101/2020.07.20.20157651doi: medRxiv preprint 
672 clusters (rings)defined
4399 contacts 
334 clusters assigned to control arm
1300 contacts (Safety sample)
1198 contacts were enrolled eligible for ITT 1116 contacts eligible for ITT
1186 contacts completed follow-up (PP sample)
52 contacts excluded  
28 not receiving any dose of study 
medication
18 treatment compliance under 
80%
6 discontinuation due to AE
1064 contacts completed follow-up (PP sample)
338 clustersassignedtointervention arm
1225 contacts (Safety sample)
12 contacts excluded 
12 cross-over to treatment 
102 individuals excluded
10 screening failure (10 symptomatic at 
baseline)
92 no PCR measurement at day 14
14 consent withdrawn
55 lost-to-follow-up
21 no PCR available on day 14
1 cross-over
1 death non-Covid related
109 individuals excluded
12 screening failure (10 symptomatic at 
baseline, 2 aged <18years)
97 no PCR measurement at day 14
13 consent withdrawn
45 lost-to-follow-up
22 no PCR available on day 14
7 patient’s decision to discontinue treatment
8 discontinuation due to AE
2 death non-Covid related
754 index cases assessed for eligibility
82 cases were not considered for inclusion 
(i.e. rings not defined) because of 
delayed reporting of more than 7 
days since start of symptoms
1874 contacts not considered for inclusion
32 known history of cardiac arrythmia or other 
comorbidity
33 dementia or severe mental illness
12 contraindicated medication
537 Covid-19 like symptos at baseline
1193 do not sign informed consent
4 more than 7 days from initial exposure
4 aged<18 years
15 pregnantor breastfeeding 
3 severe Covid-19 disease
2 taking study medication
39 others
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RR 1.18 CI95% 1.08-1.29
RR 1.56 CI95% 1.21-2.01
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